IP Library Granted Patent US 9,308,180
Granted Patent B2
US 9,308,180 · App. 13/408,994 · Granted Apr 12, 2016

Compositions and methods for preparation of poorly water soluble drugs with increased stability

Inventors: Tapas De (Los Angeles, CA); Neil P Desai (Los Angeles, CA); Andrew Yang (Rosemead, CA); Zachary Yim (Los Angeles, CA); Patrick Soon-Shiong (Los Angeles, CA)
Assignee: Abraxis BioScience, LLC
A61K9/5169A61K9/0019A61K9/19A61K31/337A61K38/13A61K45/06A61K47/26A61K47/42Y10S977/702Y10S977/705Y10S977/773Y10S977/788Y10T428/2982
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,308,180
App. No.
13/408,994
Granted
Apr 12, 2016
Kind
B2
Abstract

The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions, for example upon dilution for administration.

Claims (5)

1. A method of treating cancer in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising docetaxel and a biocompatible polymer, wherein the nanoparticles in the composition have an average or mean particle size of no greater than about 200 nm, wherein the biocompatible polymer is albumin and wherein the docetaxel used for preparation of the composition is in an anhydrous form.

2. The method of claim 1 , wherein the cancer is prostate cancer.

3. A method of treating cancer comprising administering an effective amount of a composition comprising: 1) nanoparticles comprising docetaxel and a biocompatible polymer, wherein the nanoparticles in the composition have an average or mean particle size of no greater than about 200 nm, wherein the biocompatible polymer is albumin and 2) citrate, wherein stability of the composition is enhanced as compared to that of a composition without the citrate.

4. The method of claim 3 , wherein the cancer is prostate cancer.

5. The method of claim 3 , wherein the citrate is sodium citrate.

Assignments (2)
MERGER Recorded Aug 5, 2015
From: ABRAXIS BIOSCIENCE, INC.
To: ABRAXIS BIOSCIENCE, LLC
Reel/Frame 036261/0935 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2015
From: DE, TAPAS; DESAI, NEIL P.; YANG, ANDREW; YIM, ZACHARY; SOON-SHIONG, PATRICK, M.D.
To: ABRAXIS BIOSCIENCE, INC.
Reel/Frame 036146/0117 →
Continuity (6)
Continuation 12874965 · Sep 2, 2010
Continuation 11513756 · Aug 30, 2006
Provisional Application 60712865 · Aug 31, 2005
Provisional Application 60736962 · Nov 14, 2005
Provisional Application 60736931 · Nov 14, 2005
Related Publication 20120308612A1 · Dec 6, 2012